Degrader-Antibody Conjugates: The Next Generation of ADCs

• Overviewing principles of targeted protein degraders to improve specificity of tumor-cell killing
• Explore the advantages of TPDs as therapeutic payloads
• Assessing the applications for degrader-antibody conjugates in oncology and immunology as the future of precise targeting

Speakers:

Yoshitsugu Shitaka

Chief Executive Officer

RealizeEdge